balixafortide + eribulin

Balixafortide + eribulin is a combination therapy investigated for the treatment of HER2-negative locally recurrent or metastatic breast cancer. Balixafortide is a potent and selective antagonist of the chemokine receptor CXCR4, a G-protein coupled receptor involved in tumor microenvironment modulation and immune cell trafficking. By inhibiting CXCR4, balixafortide disrupts tumor-protective signaling and may sensitize cancer cells to chemotherapy. Eribulin is a microtubule dynamics inhibitor (a synthetic analog of halichondrin B) that interferes with mitotic spindle formation, leading to apoptosis in rapidly dividing cells. The combination was developed to exploit potential synergy between disrupting the tumor microenvironment (balixafortide) and direct cytotoxicity (eribulin). Clinical trials have shown that while early-phase studies suggested promising activity with manageable safety profiles in heavily pretreated patients, later phase 3 data did not demonstrate improved objective response rates or clinical benefit over eribulin monotherapy[1][2][3][8].

Other names

eribulin mesylatePOL6326 + eribulin mesylatebalixafortide + eribulin